NCT05581823View on ClinicalTrials.gov

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 19, 2022

Primary Completion Date

January 27, 2023

Study Completion Date

February 2, 2023

Conditions
Parkinson Disease
Interventions
DRUG

Tavapadon

Oral tablets

DRUG

Carbamazepine

Extended-release oral tablets

Trial Locations (1)

53704

Madison, Wisconsin, Madison

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT05581823 - Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants | Biotech Hunter | Biotech Hunter